Trial Profile
After TURBT, Anlotinib Hydrochloride combined with radiotherapy to preserve bladder for treatment of myometrial invasive bladder cancer
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Feb 2020
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 04 Feb 2020 New trial record